Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novo Nordisk 1Q Results

Ozempic sales were DKK 29.97 billion, up 33% and Wegovy sales were DKK 9.4 billion, up 106%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk
1Q Revenues: DKK 65.3 billion (+22%)
1Q Earnings: DKK 25.4 billion (+28%)
Comments: Sales within Diabetes and Obesity care increased by 25% to DKK 61.0 billion, mainly driven by GLP-1 diabetes sales growth of 30% and Obesity care growing by 41% to DKK 11.0 billion. Ozempic sales were DKK 29.97 billion, up 33%. Wegovy sales were DKK 9.4 billion, up 106%. Rare disease sales decreased by 4%. In the quarter, Wegovy was approved in the U.S. for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease, and Awiqli, once-weekly insulin icodec, was recommended for EU approval.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters